RE:RE:SONA action at TORR starting to move higheronly "proof" is Q1 report
https://torrentcapital.ca/wp-content/themes/stratusx-child/financial-statements/torrent_capital_financial_03312020.pdf and no insider sales have occured since
let me know what you think my assumption is yes, here is the commentary from MD&A
https://torrentcapital.ca/wp-content/themes/stratusx-child/mda/torrent_capital_mda_03312020.pdf "Sona Nanotech (“SONA”) SONA is a Halifax-based, nanotechnology Life Sciences company that has developed two proprietary methods of manufacturing rod-shaped gold nanoparticles. Its principal business is the research and development of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance of existing tests in the market. Sona is currently working with GE Life Sciences to complete a rapid respond test to the Covid-19 Coronavirus test. SONA is the manufacturer of the Gemini and Omni Gold Nanorod (“GNR”) product lines. SONA is the world’s first company to develop the ability to synthesize high volumes of gold nanorods without the use of the cytotoxin, cetyltrimethylammonium bromide (“CTAB”). GNR products are ideally suited for in-vitro diagnostics test products including lateral flow assays, enzyme-linked immunosorbent assays, flow through assays and lab analyzers. Sona recently announced a transformative partnership with GE Healthcare Life Sciences to jointly complete test development of the Sona Covid-19 Coronavirus rapid response lateral flow test. The test will utilize GE Healthcare Life Sciences’ FFHP Membrane, which is specifically designed to allow for multiple optimization techniques (potentially allowing the test to become market ready sooner) and fast flow performance (potentially allowing for faster individual test results). Sona will retain all commercial rights to the resulting test. Development work on Sona’s new test to measure the Covid-19 virus is underway in 3 separate labs in Canada, the UK and Germany. The company has an ongoing, open dialogue with regulators to ensure the Sona’s test is being developed within the parameters regulators have outlined. This approach will allow Sona to be eligible for FDA review through their Emergency Use Authorization (EUA) pathway and a fasttrack to market. SONA currently has a market cap of $90 million, which Torrent believes is modest compared to its potential. The company has been transformed by the prospects of its Covid-19 lateral flow test, and is on the front lines as the private sector aims to find promising technologies to assist with the current pandemic."